SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend]
SEC Accession No. 0001193125-22-156249
Filing Date
2022-05-20
Accepted
2022-05-20 16:50:10
Documents
16
Period of Report
2021-12-31

Document Format Files

Seq Description Document Type Size
1 10-K/A d304628d10ka.htm   iXBRL 10-K/A 43421
2 EX-31.1 d304628dex311.htm EX-31.1 5654
3 EX-31.2 d304628dex312.htm EX-31.2 11490
  Complete submission text file 0001193125-22-156249.txt   252068

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA ngm-20211231.xsd EX-101.SCH 4653
5 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE ngm-20211231_cal.xml EX-101.CAL 654
6 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE ngm-20211231_def.xml EX-101.DEF 1659
7 XBRL TAXONOMY EXTENSION LABEL LINKBASE ngm-20211231_lab.xml EX-101.LAB 21882
8 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE ngm-20211231_pre.xml EX-101.PRE 17499
10 EXTRACTED XBRL INSTANCE DOCUMENT d304628d10ka_htm.xml XML 7552
Mailing Address 333 OYSTER POINT BOULEVARD SOUTH SAN FRANCISCO CA 94080
Business Address 333 OYSTER POINT BOULEVARD SOUTH SAN FRANCISCO CA 94080 650-243-5555
NGM BIOPHARMACEUTICALS INC (Filer) CIK: 0001426332 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-K/A | Act: 34 | File No.: 001-38853 | Film No.: 22948396
SIC: 2834 Pharmaceutical Preparations